	I.1. Consignor				I.2. IMSOC reference	I.2.a. Local refere	nce		
	Name Address					I.3. Central Comp	etent Authority		
	Country		ISO Code			I.4. Local Compete	ent Authority		
nsignment	I.5. Consignee Name Address Country		ISO Code		I.6. Operator conducting assembly operator establishment Name Address Approval Number		ently of an		
္သု					Country	ISO Code			
o uo	I.7. Country of orig	gin		ISO Code	I.9. Country of destination		ISO Code		
Ē	I.8. Region of origi	in		Code	I.10. Region of destination		Code		
Part I: Description of consignment	I.11. Place of dispatch Name Address Approval Number Country ISO Code				I.12. Place of destination         Name         Address         Approval Number         Country       ISO Code				
	I.13. Place of loadi	ng			I.14. Date and time of departure				
	Name Address Approval Number Country	r	ISO Code						
	I.15. Means of Tra	nsport			I.16. Transporter				
	Mode	International transport	Identification		Name				
		document			Address Activity ID				
					Country	ISO Code			
					I.17. Accompanying documents				
					Accompanying document reference				
					Date of issue Country Place of issue				
	I.18. Transport con	nditions							
	Ambient 🗆		Chille	ed 🗆	Frozen				
	I.19. Container No	/ Seal No							
	I.20. Certified as Travelling circus/a	animal act 🛛	Quarantine or sin establishment 🗖	nilar	Organic fertilizers and soil improvers	Confined establis	nment 🗆		
	Slaughter 🗆		Dispatch centre	]	Further processing $\Box$	Registered equida			
	Germinal product		Exhibition 🗆	_	Event or activity near borders	Release into the w	rild 🗆		
	Products for huma	an consumption	Further keeping		Ornamental aquaculture establishment 🗆	Other 🗌			
	Relaying 🗆		Live aquatic anim consumption 🗌	als for human	Technical use 🗆				
	I.21. For transit th	rough a third coun	ıtry						
	Third country Exit point				ISO Code BCP code				
	Entry point				BCP code				
	I.22. For transit th	rough Member Sta	te(s)		I.23. For export				
	Member State		ISO Code		Third country Exit point	ISO Code BCP code			
	I.24. Estimated jou	ırney time			I.25. Journey Log				
	I.27. Total quantity	У			I.28. Total gross weight				
	I.30. Description o	f consignment							
	<b>1. 01</b> LIVE ANIMA	LS							
	0106 Other live	animals							

01061300 Camels	other camelids (Camelidae) and other camelids (Camelidae)	<b>x1</b> , (6), (1), (1), (1), (1), (1), (1), (1), (1	
. Commodity	Sex	Identification system	Identification Number
ecies	Quantity	Age	

_	KOI LAN					establistilleri					
	II. Health info	ormation									
	I, the unde	rsigned offi	cial veterin	arian, hereb	by certify, tha	t:					
	II.1.	.The anima	als(1) in the consignment described in Part I meet the following requirements:								
		II.1.1.	Their confined establishment of dispatch is approved in accordance with Articles 97 and 99 of Regulation (EU) 2016/429.								
r al l II. Cel ull'autol		II.1.2.	listed in An examination	nnex of Com on, or wher 48 hour per	nmission Imp e this is not p	s or symptoms of diseases, in particular relevant diseases plementing Regulation (EU) 2018/1882, during the clinical possible, a clinical inspection, which was carried out departure of the consignment, on (insert					
מדרדי	II.2.	According health req	to official information, animals in the consignment described in Part I meet the following direments:								
ÿ		II.2.1.	-		fined establis to be moved.	shment that is not subject to	movement restrictions				
	(2)(3) 🗆 either	[II.2.2.	(serotypes	They originate from a Member State or a zone free from infection with bluetongue virus (serotypes 1-24), where no case of infection with bluetongue virus (serotypes 1-24) has been							
			vaccinated 60 day per	confirmed during the last 24 months in the targeted animal population and have not been vaccinated with a live vaccine against infection with bluetongue virus (serotypes 1-24) in t 60 day period before the date of movement and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Commission Delegated Regulation (EU) 2020/688 are fulfilled 1							
	(2)(3) □ [II.2.2. They originate from a Member Sta and/or infection with bluetongue virus (so 32(1)(a), (b) or (c) or Article 32(2) or they					rotypes 1-24) and the requir	ements laid down in Article				
(2) 🗆 either [II.2.2.1. have been kept in a Mer					ember State or zone seasonally free from infection with types 1-24) in accordance with Article 40(3) of Commission EU) 2020/689						
		(2)	🗆 either	[II.2.2.1.1.	for at least (	50 days prior to the date of n	novement]]				
		(2)	□ and/or		for at least 2 subjected to samples col animal into	28 days prior to the date of n a serological test, with nega lected at least 28 days follow	novement and have been ative results, carried out on ring the entry date of the easonally free from infectior				
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at the Member	•	sults, carried out on samples entry date of the animal into				
	(2)	□ and/or	[II.2.2.2.	place of de			during transportation to the gainst attacks by vectors in a				
		(2)	🗆 either	[II.2.2.2.1.	for at least (	60 days prior to the date of n	novement]] .				
		(2)	□ and/or	[II.2.2.2.2.	subjected to samples col	28 days prior to the date of n a serological test, with nega lected at least 28 days follow nent of the period of protect	tive results, carried out on ring the date of the				
		(2)	□ and/or	[II.2.2.2.3.	subjected to collected at	•	sults, carried out on samples late of the commencement o				
	(2)	□ and/or	[II.2.2.3.			gainst those serotypes from were reported during the p					

	II. Health info	ormation							
				State or zo	ne and are w	vithin the im	munity period g	uaranteed in the	
				specification	ons of the va	ccine and			
		(2)	🗆 either	[II.2.2.3.1.	have been v movement]		ore than 60 days	s before the date of	-
Part II: Certification		(2)	□ and/or	[II.2.2.3.2.	PCR test, wi	ith negative i	results on sample	d vaccine and subj es collected at least e specifications of t	14 days
rt II: Ceri	(2)	□ and/or	[II.2.2.4.	specific an	itibodies agai	inst all seroty		gical test able to de ction with bluetong te or zone and	
Pai		(2)	□ either	[II.2.2.4.1.			oeen carried out of movement]]	on samples collect	ed at least
		(2)	□ and/or	[II.2.2.4.2.	2. the serological test has been carried out on samples collected at least 30 days before the date of the movement and the animal has been subjected to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of movement;]]]				
	(2)(3) 🗆 and/or	[II.2.2.	virus (sero bluetongu	otypes 1-24) e virus (serc	nor covered otypes 1-24) a	by the eradion of the the by the eradion of the by	cation programn	n infection with blu ne for infection wit wn in Article 32(1)( Ifilled, and they	h
	(2)	□ either	[II.2.2.1.	place of de		d have been	kept protected a	luring transportati gainst attacks by ve	
		(2)	🗆 either	[II.2.2.1.1.	for at least	60 days prio	r to the date of m	novement]]	
		(2)	□ and/or	[II.2.2.1.2.	subjected to samples col	o a serologica llected at lea	al test, with nega st 28 days follow	novement and have tive results, carried ing the date of the ion against attacks	d out on
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at	o a PCR test, least 14 day	with negative re	novement and have sults, carried out or ate of the commen by vectors;] ]]	n samples
	(2)	□ and/or	[II.2.2.2.	establishm centred on requireme	nent situated a the establish ents laid down	in a Membe hment, wher n in Sections	r State or in an a re surveillance in a 1 and 2 of Chap	o departure in an rea of at least 150 k compliance with t ter 1 of Part II of Ar d out during that p	he nnex V to
		(2)	□ either	[II.2.2.2.1.	24 of infect the past 2 y place where	ion with blue ears in an ar e the animal	etongue virus wh ea of at least 150 s were kept and	st those serotypes f nich were reported ) km radius centred are within the imm of the vaccine and	during l on the
			(2)	🗆 either	[II.2.2.2.1.1.	have been v of moveme		than 60 days befor	e the date
			(2)	□ and/or	[II.2.2.2.1.2.	have been v subjected to collected at	vaccinated with a of a PCR test, with	an inactivated vacc negative results on er the onset of the ne vaccine;]]]]	n samples
		(2)	□ and/or	[II.2.2.2.2.	24 of infect the past 2 y	ion with blue ears in an ar	etongue virus wł	ist those serotypes nich were reported ) km radius centred	during

II. Booth information       (2)       • either       [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 50 days before the date of movement]]         (2)       • or       [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected at lease 30 days before the date of the movement and the application of the analysis of the movement is and the subjected with positive results carried out on samples collected at lease 30 days before the date of movement and the date of movement and the set of origin authorised novement is antimals to another Member State of origin authorised novement is antimis to another Member State of control the Commission and the other Member State of action in factorial state state state. In the Member State of a control (EU) 2020(689 and the competent authority of the Member State of action is referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (c))         (2)       either       III.2.2.1.       point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       III.2.2.1.4. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and <td< th=""><th>_</th><th>-</th><th>KOI LAN</th><th></th><th></th><th></th><th></th><th></th><th><u> </u></th></td<>	_	-	KOI LAN						<u> </u>
Image: Second			II. Health info	ormation					
1000000000000000000000000000000000000					(2)	∘ either	[II.2.2.2.2.1.	a serological test carried out on samples collected at lea	
(2)       □ either       [II.2.2.1.]       with the status free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State state state submitted subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       □ either       [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and         (2)       □ and/or       [II.2.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State stat such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       □ and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to	ertification	eruncation			(2)	0 or	[II.2.2.2.2.2.	a serological test carried out on samples collected at lea 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of	
the Member State of destination has informed the commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020(688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled.]]]         (2)       and/or       [II.2.2.2.4) with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of Astat Such Novement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and         (2)       either       [II.2.2.2.2]       point 5 of Section	<b>O</b> It tr(2)(3) □[II.2.2.They do not fulfil the requirements laid down in points 1 to 3 of Sec Part II of Annex V to Regulation (EU) 2020/689 and the competent a State of origin authorised movement of those animals to another M thereof						U) 2020/689 and the competent authority of the Member		
L       Delegated Regulation, and         (2)       and/or       [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States that such movement is authorised subject to the conditions referred to in Article 32(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(688 and         (2)       either       [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and		the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689							
(2)       and/or       [II.2.2.1.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.       with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.2.1.       point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.3.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [				(2)	□ either	[II.2.2.1.1.			
Part of the second s				(2)	□ and/or	[II.2.2.1.2.	-	-	
Delegated Regulation, and         the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.2.       with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation are fulfilled;]]]         (2)       and/or </td <th></th> <td></td> <td></td> <td>(2)</td> <td>□ and/or</td> <td>[II.2.2.1.3.</td> <td></td> <td></td> <td></td>				(2)	□ and/or	[II.2.2.1.3.			
32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.3. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the o				(2)	□ and/or	[II.2.2.1.4.	-	-	
<ul> <li>(serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and</li> <li>(2) □ either [II.2.2.2.1] point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.2] point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.3] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) □ and/or [II.2.2.3] neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State stat such movement is authorised</li> <li>(2) □ either [II.2.2.3.] without any conditions, and</li> <li>(2) □ either [II.2.2.3.] without any conditions, and</li> <li>(2) □ and/or [II.2.3.2.] subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/688, and</li> </ul>							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements	
Delegated Regulation, and       (2)       and/or       [II.2.2.2.2.       point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.3.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.3.1.       meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commi	(2) □ and/or [II.2.2				[II.2.2.2.	(serotypes Commission subject to	1-24) and the ot the condition	e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated	
Cancel and/or       [II.2.2.3.]       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         Cancel C				(2)	□ either	[II.2.2.2.1.			
<ul> <li>(2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) either [II.2.2.3.1. without any conditions, and</li> <li>(2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>				(2)	$\Box$ and/or	[II.2.2.2.2.			
<ul> <li>Delegated Regulation, and</li> <li>the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) either [II.2.2.3.1. without any conditions, and</li> <li>(2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>				(2)	$\Box$ and/or	[II.2.2.2.3.			
<ul> <li>32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) either [II.2.2.3.1. without any conditions, and</li> <li>(2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>				(2)	□ and/or	[II.2.2.2.4.	-	-	
<ul> <li>by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) □ either [II.2.2.3.1. without any conditions, and</li> <li>(2) □ and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements	
(2)			(2)	□ and/or	[II.2.2.3.	by the erac 24) and the	dication prog e Member St	gramme for infection with bluetongue virus (serotypes 1 ate of destination has informed the Commission and the	l-
(2)				(2)	🗆 either	[II.2.2.3.1.	without any	y conditions, and	
							subject to th	he conditions referred to in point 5 of Section 1 of Chapt	er
				(2)	□ and/or	[II.2.2.3.3.			er

	II. Health info	rmation							
	n. nearth hno	Titlation							
	2 of Part II of Annex V to D						egu	lation (EU) 2020/689, and	
		(2)	□ and/or	[II.2.2.3.4.		e conditions referred to in of Annex V to Delegated Re	-	oint 7 of Section 1 of Chapter lation (EU) 2020/689, and	
	(2)								
Part II: Certification					32(2) of Dele	nents laid down in Article egated Regulation (EU) 202 n Article 33 of that Delegat	20/6		
<mark>.</mark>	II.3	To the bes	t of my know	wledge and a	as declared b	y the operator:			
II.3.1. In the confined establishment of dispatch there are no abnormal mortalities with a undetermined cause affecting the animals to be moved.								l mortalities with an	
		II.3.2.				nct with animals which are .1., or with animals of a low		-	
		II.3.3.							
	II.4.	-	ents are ma 1 (EU) 2020/6	-	ort the consig	gnment in accordance witl	h A	rticle 4 of Delegated	
	II.5.	animals, th		10 days for				ansport by waterway/sea of nded by the duration of the	
	lumpy skir		compliance			n relation to emergency pr d Annex IX, Part 3, point (3		ective vaccination against ), to Commission Delegated	
	skin diseas		iance with A			lation to emergency protec x IX, Part 3, point (3.2), to (		ve vaccination against lumpy nmission Delegated	
	Animal we	lfare attesta	ation						
		ovisions of				h certificate were fit to be n the intended journey due			
	Notes:								
	In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Union in this certificate include the United Kingdom in respect of Northern Ireland.								
	This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.								
	Part I:								
	Box reference I.11:		lispatch": In ion (EU) 201		fined establis	shment approved in accore	dar	nce with Articles 97 and 99	
	Box reference I.12:		lestination": lation (EU) :		confined esta	blishment approved in acc	cor	dance with Articles 97 and	
	Part II:								
	(1)	There can	be one or m	nore animals	s in the consig	gnment.			
	(2)	Delete if n	ot applicabl	e.					

	II. Health info	rmation		
	(3)	Only in case of animals belonging to the family Giraffidae, Moschidae or Tragulidae.	ies Antilocapridae, Bovidae, C	amelidae, Cervidae,
	Certifying Off	icer/Official veterinarian		
	Name (in capi	tal letters)	Qualification and title	
n	Date of signat Stamp	ure	Signature	
Part II: Certification	Stamp			
ũса				
rtif				
Ce				
t II:				
art				
Н				